莫桑比克轮状病毒疫苗接种的成本效果
莫桑比克2015年引入ROTARIX轮状病毒疫苗但成本效果未明,本研究用决策支持模型估算2016-2020年ROTARIX对比不接种、以及2021-2030年ROTARIX、ROTAVAC、ROTASIIL三种疫苗对比不接种和相互对比的成本效果,主要结局为政府视角每避免一个伤残调整生命年(DALY)的增量成本。
要点
- 每避免一个DALY的成本为70美元。
核心结论
- ROTARIX接种在2016-2020年间对莫桑比克产生了实质性的公共卫生影响。
- ROTARIX目前估计是最具成本效果的产品,但随着关于各轮状病毒疫苗价格、增量配送成本、损耗和影响的更多证据出现,疫苗选择应重新评估。
研究设计与样本
- 使用决策支持模型计算疫苗接种对比不接种的潜在成本效果。
- 2016-2020年五年期比较ROTARIX与不接种;2021-2030年十年期比较ROTARIX、ROTAVAC和ROTASIIL与不接种及相互之间。
- 主要结局为政府视角下每避免一个DALY的增量成本,并通过敏感性分析评估不确定性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rotavirus is one of the most common cause of severe gastroenteritis in children, with the largest mortality burden in low- and middle-income countries. To prevent rotavirus gastroenteritis, Mozambique introduced ROTARIX® vaccine in 2015, however, its cost-effectiveness has never been established in the country. In 2018, additional vaccines became available globally. This study estimates the cost-effectiveness of the recently introduced ROTARIX in Mozambique and compares the cost-effectiveness of ROTARIX®, ROTAVAC®, and ROTASIIL® to inform future use. METHODS: We used a decision-support model to calculate the potential cost-effectiveness of vaccination with ROTARIX compared to no vaccination over a five-year period (2016-2020) and to compare the cost-effectiveness of ROTARIX, ROTAVAC, and ROTASIIL to no vaccination and to each other over a ten-year period (2021-2030). The primary outcome was the incremental cost per disability-adjusted life-year (DALY) averted from a government perspective. We assessed uncertainty through sensitivity analyses. RESULTS: From 2016 to 2020, we estimate the vaccine program with ROTARIX cost US$12.3 million, prevented 4,628 deaths, and averted US$3.1 million in healthcare costs. The cost per DALY averted was US$70. From 2021 to 2030, we estimate all three vaccines could prevent 9,000 deaths and avert US$7.8 million in healthcare costs. With Global Alliance for Vaccines and Immunization (Gavi) support, ROTARIX would have the lowest vaccine program cost (US$31 million) and 98 % probability of being cost-effective at a willingness-to-pay threshold of 0.5x GDP per capita. Without Gavi support, ROTASIIL would have the lowest vaccine program cost (US$75.8 million) and 30 % probability of being cost-effective at the same threshold. CONCLUSION: ROTARIX vaccination had a substantial public health impact in Mozambique between 2016 and 2020. ROTARIX is currently estimated to be the most cost-effective product, but the choice of vaccine should be re-evaluated as more evidence emerges on the price, incremental delivery cost, wastage, and impact associated with each of the different rotavirus vaccines.
引用
- Lourenço Guimarães E, Chissaque A, Pecenka C, et al. Cost-effectiveness of rotavirus vaccination in Mozambique. Vaccine. 2022. PMID: 35933279. doi:10.1016/j.vaccine.2022.07.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。